INDICATION AND IMPORTANT SAFETY INFORMATION
TOBI® Podhaler® (Tobramycin Inhalation Powder) 28 mg per capsule is indicated for the management of cystic fibrosis patients with Pseudomonas aeruginosa.  ...More

COUNSELING TOBI® PODHALER® PATIENTS

Set treatment expectations with your patients

ACKNOWLEDGE

Cough is a common symptom of cystic fibrosis.1

In a clinical trial, patients taking TOBI Podhaler reported a higher incidence of cough than patients taking TOBI® (Tobramycin Inhalation Solution, USP) during the first week of active treatment.1

EDUCATE

After the first week of treatment in the same study, the time to first cough was similar in patients taking TOBI Podhaler and patients taking TOBI.1

Five percent of patients taking TOBI Podhaler discontinued due to cough compared with 1% of patients taking TOBI.1

TRAIN

Patients and caregivers should be initially trained by their health care provider on the proper use of TOBI Podhaler.

In addition to the training you provide your patients, advise them to read the Patient Information and the full Instructions for Use. Please see additional information and helpful tips below.

Instructions and tips to help with inhaling TOBI Podhaler1

  • PRACTICE WITH THE TOBI PODHALER INHALATION TRAINER
  • DO NOT PRESS THE BLUE BUTTON ON THE PODHALER
    DEVICE MORE THAN ONCE, AS THE CAPSULE MAY BREAK
    INTO PIECES1
    • Be sure not to swallow capsules1
    • Capsules are for oral inhalation only1
    • Capsules are to be used with the Podhaler device only1
  • TILT HEAD BACK SLIGHTLY WHEN INHALING2
  • INHALE DEEPLY WITH A SINGLE BREATH1,2
    • Practice may help your patients find the best inhalation speed
      for them
  • TAKE A SIP OF WATER AFTER ADMINISTERING2

Important Dosing Considerations

  • Patients and caregivers should be initially trained by their health care provider on the proper use of TOBI Podhaler
  • TOBI Podhaler capsules must not be swallowed
  • Capsules are for use with the Podhaler device only
  • Capsules are for oral inhalation only
  • Each dose of 4 capsules should be taken as close to 12 hours apart as possible; each dose should not be taken less than 6 hours apart
  • Capsules should always be stored in the blister card; each capsule should only be removed immediately before use

Please see full Prescribing Information and complete Instructions for Use.

A centralized support and access program for TOBI® Podhaler® patients

Learn more

SET TREATMENT EXPECTATIONS

Inform your patients about what to expect while taking TOBI® Podhaler®

Learn more

ADMINISTRATION INFORMATION

Administration information and helpful tips for patients taking TOBI® Podhaler®

Learn more

Share

To share this website with other health care professionals, please choose your email service provider:

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION

TOBI® Podhaler® (Tobramycin Inhalation Powder) 28 mg per capsule is indicated for the management of cystic fibrosis patients with Pseudomonas aeruginosa.

Safety and efficacy have not been demonstrated in patients under the age of 6 years, patients with forced expiratory volume in
1 second
(FEV1) <25% or >80% predicted, or patients colonized with Burkholderia cepacia.